Andreas Schulze-Bonhage
University of Freiburg
558 Papers
2.1K Citations
Andreas Schulze-Bonhage is an academic researcher from University of Freiburg. The author has contributed to research in topics: Epilepsy & Medicine. The author has an hindex of 67, co-authored 495 publications. Previous affiliations of Andreas Schulze-Bonhage include University Medical Center & Harvard University.
Chat about Author
Papers
Deep Convolutional Networks for Automated Detection of Epileptogenic Brain Malformations
Ravnoor S. Gill,Seok-Jun Hong,Fatemeh Fadaie,Benoit Caldairou,Boris C. Bernhardt,Carmen Barba,Armin Brandt,Vanessa Cristina Mendes Coelho,Ludovico D'Incerti,Matteo Lenge,Mira Semmelroch,Fabrice Bartolomei,Fernando Cendes,Francesco Deleo,Renzo Guerrini,Maxime Guye,Graeme D. Jackson,Andreas Schulze-Bonhage,Tommaso Mansi,Neda Bernasconi,Andrea Bernasconi +20 more
- 16 Sep 2018
TL;DR: Easy implementation, minimal pre-processing, high performance and generalizability make this classifier an ideal platform for large-scale clinical use, particularly in “MRI-negative” FCD.
24
Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials.
Basim M. Uthman,Carl W. Bazil,Ahmad Beydoun,Andreas Schulze-Bonhage,Reina Benabou,Ed Whalen,Birol Emir,T. Griesing,Teresa Leon +8 more
TL;DR: The objective is to evaluate the safety, tolerability, and efficacy of long‐term pregabalin as add‐on therapy for patients with poorly controlled partial seizures.
24
Lack of psychotomimetic or impairing effects on psychomotor performance of acamprosate.
Udo Schneider,Wohlfahrt K,Andreas Schulze-Bonhage,Tilmann Haacker,Caspary A,Markus Zedler,Hinderk M. Emrich +6 more
TL;DR: A dose of acamprosate of 2 g/day for seven days was free of any significant effects on mood, concentration, attention, psychomotor performance and did not produce any subjective sedation, excitation or psychotomimetic effects.
23
Disorganization of neocortical lamination in focal cortical dysplasia is brain-region dependent: evidence from layer-specific marker expression
Susanne Fauser,Susanne Fauser,Ute Häussler,Catharina Donkels,Susanne Huber,Julia M Nakagawa,Marco Prinz,Andreas Schulze-Bonhage,Josef Zentner,Carola A. Haas +9 more
TL;DR: The data suggest that late cortical development is disturbed in FCD, yet most likely by different causes depending on brain region, FCD type and FCD severity.
Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study
Fabienne Kühne,Lena-Luise Becker,Thomas Bast,Astrid Bertsche,Ingo Borggraefe,Christian Boßelmann,J. Fahrbach,Christoph Hertzberg,Nina A Herz,Martin S. Hirsch,Martin Holtkamp,Christine Janello,Gerhard Kluger,Gerhard Kurlemann,Holger Lerche,Konstantin L. Makridis,Felix von Podewils,Milka Pringsheim,Susanne Schubert-Bast,Juliane Schulz,Andreas Schulze-Bonhage,David Steinbart,Bernhard J. Steinhoff,Adam Strzelczyk,Steffen Syrbe,Heike de Vries,Christian Wagner,Johanna Wagner,Bernd Wilken,Christine Prager,Kerstin Alexandra Klotz,Angela M. Kaindl +31 more
TL;DR: Cannabidiol (CBD) is approved for treatment of Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC) as mentioned in this paper .
23